ChinaBio® Day Unveils Program Highlights
CARLSBAD, Calif. & SAN FRANCISCO-(Business Wire)-September 10, 2009 - EBD Group and ChinaBio® LLC, today unveiled program highlights for the ChinaBio® Day event to be held on September 15, 2009 at the San Francisco Marriott. In the heart of the American biotech industry, this unique event will provide insights into recent developments of the rapidly changing life science industry in China.
The program features leading industry executives from both sides of the Pacific to discuss partnering opportunities between China and the rest of the world and what it takes to succeed in China.
To learn more about any of the sessions below, please visit the ChinaBio® Day program page at http://www.ebdgroup.com/cbd/program.htm.
Cross-Border Partnerships — Leveraging China's Resources: China is rapidly becoming a global center for drug research and development, attracting the world's leaders in pharma and biotech. Companies are seeking a variety of partnership opportunities to leverage China's strong basic research, talented scientific staff, and low cost structure. Greg Scott, President and Founder, ChinaBio LLC moderates a panel featuring Samantha Du, PhD, CEO, Hutchison MediPharma; Michael Heerde, PhD, MBA, Director, Strategy and Business Development, Bayer HealthCare China; James M. Schaeffer, PhD, Executive Director, Licensing and External Research, Merck & Co., Inc.; and Steve Yang, PhD, VP and Head of R&D Asia, Pfizer Global Research in an exploration of what to look for and how to evaluate partnering opportunities in China.
The Impact of the Financial Crisis on Partnering in China: The financial turmoil has impacted partnering activities around the globe, but China seems to have turned the crisis into an opportunity. Taking advantage of the China government's stimulus and development programs, and the increasingly strong economy in China, companies that might be struggling elsewhere have been able to continue to secure funding and move their programs forward in China. Stephen B. Thau, JD, Partner and Co-chair of Life Sciences Group, Morrison & Foerster will lead a panel that includes Frank Kung, PhD, MBA, Managing Partner, Vivo Ventures; Yuwen Liu, MS, MBA, General Manager, BioBay; Hongbo B. Lu, PhD, MBA, VP and Senior Research Analyst, Piper Jaffray & Co.; and William Molloie, Partner, PricewaterhouseCoopers in a discussion on why China seems to be on the leading edge of recovery, and what the future holds for the pharma industry around the world.
Successful Partnerships in China — Case Studies: Many Western companies are pursuing partnerships in China to form R&D collaborations, gain access to the vast Chinese market and improve the speed of drug development while reducing costs. Executives from companies that are already actively partnering in China, such as Ruediger Herrmann, PhD, Partner, WilmerHale; R. Stephen Porter, PharmD, CSO, Medicilon-MPI Preclinical Research; Yingfei Wei, PhD, CSO, 3SBio, Inc.; Frank Torti, MD, Senior Associate, New Enterprise Associates; and Guo-Liang Yu, PhD, President and CEO, Epitomics will reveal how they achieved successful relationships and overcame the geographic, legal and cultural issues associated with cross-border partnerships.
How to Partner with China Life Science Companies — Factors for Success: There are many factors that determine the success—or failure—of partnerships in any location, and China brings its own unique set of requirements for success. Ellen Leznik, MBA, JD, Founding Partner, Virtual Law Partners LLP will be joined by Jie Liu D’Elia, PhD, MBA, VP, International Business Development, Simcere Pharmaceutical Group; Joanne Jiang, PhD, MBA, VP, Business Development and International Project Management, Fountain Medical Development Ltd.; Brian Moloney, PhD, VP, Business Development, BioDuro, Inc.; and Yu Zhao, PhD, VP, Tianjin International Joint Academy of Biotechnology and Medicine in a practical, "how to” approach to partnering in China, examining the legal, IP, staffing and cultural issues that can affect consummating and managing cross-border partnerships in China.
Registration for this first time event is USD 395.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations, and include:
- BIO-Europe and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- EuroMedtech™, EBD Group’s new partnering event for the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio LLC
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives
EBD Group’s sophisticated web-based partnering service, partneringONE™, is used as the partnering engine at numerous third-party events around the world.
Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information visit www.ebdgroup.com.
About ChinaBio® LLC
Since its founding in January, 2007, ChinaBio LLC has rapidly launched a number of successful initiatives connecting China biotech with the world. With offices in Shanghai, Silicon Valley and San Diego, ChinaBio’s activities include:
- Conferences: Organizer of the premier life science investment and partnering forums in China.
- Consulting: Helping big pharma, entrepreneurs and investors achieve success in China.
- Accelerator: Assisting early stage China companies to raise over USD 110 million to date.
- Research: Developing in-depth research data on novel technology development, clinical trial activity, VC investment, M&A/IPO and partnering activity in China.
- ChinaBio® Today: Publishing online and email newsletters focusing exclusively on China’s life science industry.
For more information please visit www.chinabiollc.com.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
